Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More | Zendy

Benjamin Misselwitz | Zendy; Pascal Juillerat | Zendy; Michael Christian Sulz | Zendy; Britta Siegmund | Zendy; Stephan Brand | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More

Author(s) -

Benjamin Misselwitz,

Pascal Juillerat,

Michael Christian Sulz,

Britta Siegmund,

Stephan Brand

Publication year - 2020

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000507782

Subject(s) - vedolizumab , janus kinase , tofacitinib , inflammatory bowel disease , medicine , immunology , ustekinumab , pharmacology , addressin , cancer research , tumor necrosis factor alpha , cytokine , integrin , adalimumab , receptor , disease , rheumatoid arthritis

Treatment of inflammatory bowel diseases (IBD) has tremendously improved during the last 20 years; however, a substantial fraction of patients does not respond to available therapies or lose response, and new strategies are needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research